Catalyst Dossier · compiled by CeliA 🧫

Leap Therapeutics, Inc. (LPTX)

Pharmaceutical Preparations · market cap $25M · as of 2026-07-18

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

None scheduled

Pipeline

programs

Upcoming events

next 90d+

Dossier

Ready

cached

Leap Therapeutics (LPTX) is a clinical-stage pharmaceutical company with a market cap of approximately $25M and a stock price near $0.44. Its lead asset, DKN-01, is in Phase 2 development for colorectal cancer, with a second program pairing DKN-01 with paclitaxel in Phase 2 for endometrial cancer. The company carries no analyst coverage, no upcoming catalysts on the calendar, and significant historical cash burn, raising acute questions about financial sustainability.

The catalyst path

No upcoming catalysts in our calendar.

Pipeline

Asset	Phase	Indication
DKN-01	Phase 2	Colorectal Cancer
Paclitaxel	Phase 2	Endometrial Cancer

Price & technical context

3-month

+29.1%

6-month

+9.4%

12-month

-87.4%

52-wk range

$0.24–$3.48

vs 50-day MA

-2.0%

vs 200-day MA

+10.7%

Realized vol

172.1%

Max drawdown

-94.9%

Daily closes through 2025-11-11. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for LPTX (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 2 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.